i) In silico phenotype-based research and patient stratification
The CK-CARE registry collects a unique range of data from patients with atopic dermatitis (currently more than 1,200 patients) including: current severity, age of onset, detailed disease course and history, family background, associated diseases and comorbidities of patients and relatives, sociodemographic information, life style, past and current treatment regimens, intolerances, quality of life, and routine lab data. The registry contains a growing collection of follow up data. The registry offers a unique opportunity for in depth in silico analysis to better understand the complex phenotype of atopic dermatitis and its comorbidities as a valuable help for strategic decisions in drug development programs.
ii) Contracted research projects for drug and biomarker discovery.
Using the samples of the CK-CARE biorepository and the technology platform, we offer a unique opportunity to test your therapeutic approaches and strategies, new therapeutic molecules or targets or diagnostic test procedures on high quality and clinically well characterized biomaterial from patients and control individuals. The biomaterial from the CK-CARE biobank is also an ideal material for comparative studies with a well-defined population and for control purposes.
iii) Storage of samples from preclinical and clinical trials (phases I-IV).
Our experience in operating biorepositories offers the best conditions for the labeling, short/long term storage and management of biospecimen collected during preclinical and clinical procedures/trials. Including downstream analysis.
Histology and immunohistochemical staining procedures belong to the well-established investigational tools in dermatology. We offer a large panel of staining procedures using specific antibodies directed against structural and cellular features in the skin to explore the in situ impact of new compounds. In case of need of reference biopsies and for sensitivity/specificity purposes, the CK-CARE biorepository can provide adequate material from well characterized patients and control individuals. We will also be able to scan the slides for further image analysis and A.I. approaches on the stained samples.
v) Analysis of soluble mediators in liquid samples
Measurement of soluble mediators in liquid biospecimen such as serum, sputum, interstitial fluids or culture supernatants is a major pillar in biomarker programs flanking clinical drug development. Our platform offers a panel of different technologies including newest generation multiplex analysis
vi) Cellular phenotyping
Multicolor flow cytometric analysis of blood or skin samples provide a useful tool to analysis the behavior of the cells before, during and after the therapy with new compounds. Our platform is equipped with several modern multicolor flow cytometers.
vii) Transcriptome and genome analysis
We provide a state-of-the-art RNA and DNA isolation and processing for expression profiling or deep sequencing from biosamples of any kind. Sequence and array-based technologies are used for a comprehensive coverage for analysis of the samples from your program.
viii) Biomarker discovery and development services
We provide a competent project management for all above-mentioned services and help in the design of trials aiming to identify new biomarkers as potential companion diagnostics. Candidate biomarkers can be combined into panels of significant discriminatory power and thereby be used for diagnostic, prognostic or predictive purposes. Beyond discovery programs, our services can provide valuable help for validation steps as well as for regulatory qualification/fitness for use.